196 related articles for article (PubMed ID: 37138793)
1. Pro- and anti-tumour activities of CD146/MCAM in breast cancer result from its heterogeneous expression and association with epithelial to mesenchymal transition.
Mannion AJ; Odell AF; Baker SM; Matthews LC; Jones PF; Cook GP
Front Cell Dev Biol; 2023; 11():1129015. PubMed ID: 37138793
[TBL] [Abstract][Full Text] [Related]
2. Aberrant promoter methylation may be responsible for the control of CD146 (MCAM) gene expression during breast cancer progression.
Dudzik P; Trojan SE; Ostrowska B; Lasota M; Dulińska-Litewka J; Laidler P; Kocemba-Pilarczyk KA
Acta Biochim Pol; 2019 Dec; 66(4):619-625. PubMed ID: 31826047
[TBL] [Abstract][Full Text] [Related]
3. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation.
Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ
Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413
[TBL] [Abstract][Full Text] [Related]
4. CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.
Zabouo G; Imbert AM; Jacquemier J; Finetti P; Moreau T; Esterni B; Birnbaum D; Bertucci F; Chabannon C
Breast Cancer Res; 2009; 11(1):R1. PubMed ID: 19123925
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical Expression of MCAM/CD146 in Canine Melanoma.
Abou Asa S
J Comp Pathol; 2017 Jul; 157(1):27-33. PubMed ID: 28735667
[TBL] [Abstract][Full Text] [Related]
6. The Epigenetic Modifier 5-Aza-2-deoxycytidine Triggers the Expression of
Dudzik P; Trojan SE; Ostrowska B; Zemanek G; Dulińska-Litewka J; Laidler P; Kocemba-Pilarczyk KA
Anticancer Res; 2019 May; 39(5):2395-2403. PubMed ID: 31092432
[TBL] [Abstract][Full Text] [Related]
7. Critical role of the MCAM-ETV4 axis triggered by extracellular S100A8/A9 in breast cancer aggressiveness.
Chen Y; Sumardika IW; Tomonobu N; Kinoshita R; Inoue Y; Iioka H; Mitsui Y; Saito K; Ruma IMW; Sato H; Yamauchi A; Murata H; Yamamoto KI; Tomida S; Shien K; Yamamoto H; Soh J; Futami J; Kubo M; Putranto EW; Murakami T; Liu M; Hibino T; Nishibori M; Kondo E; Toyooka S; Sakaguchi M
Neoplasia; 2019 Jul; 21(7):627-640. PubMed ID: 31100639
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of soluble CD146/MCAM with the M2J-1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146-positive invasive tumors.
Stalin J; Traboulsi W; Vivancos-Stalin L; Nollet M; Joshkon A; Bachelier R; Guillet B; Lacroix R; Foucault-Bertaud A; Leroyer AS; Dignat-George F; Bardin N; Blot-Chabaud M
Int J Cancer; 2020 Sep; 147(6):1666-1679. PubMed ID: 32022257
[TBL] [Abstract][Full Text] [Related]
9. MUC18/MCAM (CD146), an activation antigen of human T lymphocytes.
Pickl WF; Majdic O; Fischer GF; Petzelbauer P; Faé I; Waclavicek M; Stöckl J; Scheinecker C; Vidicki T; Aschauer H; Johnson JP; Knapp W
J Immunol; 1997 Mar; 158(5):2107-15. PubMed ID: 9036955
[TBL] [Abstract][Full Text] [Related]
10. MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells.
Wu Z; Wu Z; Li J; Yang X; Wang Y; Yu Y; Ye J; Xu C; Qin W; Zhang Z
Tumour Biol; 2012 Oct; 33(5):1619-28. PubMed ID: 22610942
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of Melanoma Cell Adhesion Molecule (MCAM/CD146) Accelerates Cellular Senescence in Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells.
Jin HJ; Kwon JH; Kim M; Bae YK; Choi SJ; Oh W; Yang YS; Jeon HB
Stem Cells Transl Med; 2016 Apr; 5(4):427-39. PubMed ID: 26941359
[TBL] [Abstract][Full Text] [Related]
12. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer.
Zeng Q; Li W; Lu D; Wu Z; Duan H; Luo Y; Feng J; Yang D; Fu L; Yan X
Proc Natl Acad Sci U S A; 2012 Jan; 109(4):1127-32. PubMed ID: 22210108
[TBL] [Abstract][Full Text] [Related]
13. CD146 expression in human breast cancer cell lines induces phenotypic and functional changes observed in Epithelial to Mesenchymal Transition.
Imbert AM; Garulli C; Choquet E; Koubi M; Aurrand-Lions M; Chabannon C
PLoS One; 2012; 7(8):e43752. PubMed ID: 22952755
[TBL] [Abstract][Full Text] [Related]
14. Stem-Mesenchymal Signature Cell Genes Detected in Heterogeneous Circulating Melanoma Cells Correlate With Disease Stage in Melanoma Patients.
Rapanotti MC; Campione E; Suarez Viguria TM; Spallone G; Costanza G; Rossi P; Orlandi A; Valenti P; Bernardini S; Bianchi L
Front Mol Biosci; 2020; 7():92. PubMed ID: 32548126
[TBL] [Abstract][Full Text] [Related]
15. Quantitative proteomics reveals ER-α involvement in CD146-induced epithelial-mesenchymal transition in breast cancer cells.
Zeng Q; Zhang P; Wu Z; Xue P; Lu D; Ye Z; Zhang X; Huang Z; Feng J; Song L; Yang D; Jiang T; Yan X
J Proteomics; 2014 May; 103():153-69. PubMed ID: 24704855
[TBL] [Abstract][Full Text] [Related]
16. Minimal Residual Disease in Melanoma:molecular characterization of in transit cutaneous metastases and Circulating Melanoma Cells recognizes an expression panel potentially related to disease progression.
Rapanotti MC; Viguria TMS; Spallone G; Terrinoni A; Rossi P; Costanza G; Campione E; Lombardo P; Pathirannehalage CD; Orlandi A; Bernardini S; Bianchi L
Cancer Treat Res Commun; 2020; 25():100262. PubMed ID: 33338742
[TBL] [Abstract][Full Text] [Related]
17. Ectopic expression of MCAM/MUC18 increases in vitro motility and invasiveness, but decreases in vivo tumorigenesis and metastasis of a mouse melanoma K1735-9 subline in a syngeneic mouse model.
Wu GJ
Clin Exp Metastasis; 2016 Dec; 33(8):817-828. PubMed ID: 27510563
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 Is a Natural Binding Ligand of MCAM (CD146, MUC18) in Melanoma Cells and Their Interaction Promotes Melanoma Progression.
Pang Y; Maxwell E; Sindrewicz-Goral P; Shapanis A; Li S; Morgan M; Yu LG
Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291660
[TBL] [Abstract][Full Text] [Related]
19. CD146 increases stemness and aggressiveness in glioblastoma and activates YAP signaling.
Liang Y; Voshart D; Paridaen JTML; Oosterhof N; Liang D; Thiruvalluvan A; Zuhorn IS; den Dunnen WFA; Zhang G; Lin H; Barazzuol L; Kruyt FAE
Cell Mol Life Sci; 2022 Jul; 79(8):398. PubMed ID: 35790583
[TBL] [Abstract][Full Text] [Related]
20. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
